Selexipag Tablets.

Selexipag tablets are a drug for the treatment of pulmonary arterial hypertension. This product is used to treat pulmonary arterial hypertension (PAH, WHO group 1) to delay disease progression and reduce the risk of hospitalization due to PAH. The effectiveness of this product has been confirmed in a long-term study conducted in patients with PAH of WHO functional class II-III. Patients had idiopathic or hereditary PAH (58%), PAH associated with connective tissue disease (29%), and PAH associated with congenital heart disease with repaired shunts (10%).
Selexipag is an oral prostacyclin receptor (IP receptor) agonist with a structure different from prostacyclin. Selexipag is hydrolyzed by carboxylesterase 1 to an active metabolite, which is approximately 37 times more potent than selexipag. Selexipag and its active metabolites selectively act on IP receptors and have no effect on other prostaglandin receptors (EP1-4, DP, FP, and TP).